Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Continuous femoral nerve blocks (CFNB) provide effective pain control to patients undergoing total knee replacement (TKR). However the resulting motor blockade can lead to decreased quadriceps muscle strength and delayed functional recovery.The purpose of this study is to compare the effect of Liposome Bupivacaine infiltration into the knee to CFNB on pain control and functional recovery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• ASA Status I-III

• Scheduled to undergo primary unilateral total knee arthroplasty

Exclusion Criteria:

• Patients who are pregnant or nursing

• Alcohol or narcotic dependence within the last 2 years

• Condition requiring regular use of analgesia that may confound post surgical assessments as determined by principle investigator

• BMI > 40kg/m2

• Contraindication to acetaminophen, morphine, oxycodone, ketorolac, epinephrine, or pathological conditions potentially aggravated by epinephrine

• Allergies to amide-type local anesthetics

• Any disease condition or lab result that could complicate a patients postoperative recovery

• History of hypotension

• Abnormal liver, renal or cardiac function

• Other physical, mental or medical conditions that, in the opinion of the investigator, make study participation inadvisable.